Increased levels of the soluble adhesion molecule E‐selectin in patients with chronic myeloproliferative disorders and thromboembolic complications

• Published in: American journal of hematology Vol. 57; no. 2; pp. 109 - 112
• Main Authors: Musolino, Caterina, Alonci, Andrea, Allegra, Alessandro, Spatari, Giovanna, Bellomo, Giacomo, Tringali, Orazio, Quartarone, Cristina, Squadrito, Giovanni, Quartarone, Melchiorre
• Format: Journal Article
• Language: English
• Published: New York Wiley Subscription Services, Inc., A Wiley Company 01.02.1998; Wiley-Liss
• Subjects: Adult; Biological and medical sciences; Biomarkers; Chronic Disease; E-Selectin - blood; endothelial damage; Female; Hematologic and hematopoietic diseases; Humans; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Male; Medical sciences; Middle Aged; myeloproliferative disorders; Myeloproliferative Disorders - blood; Myeloproliferative Disorders - complications; soluble E‐selectin; soluble thrombomodulin; Thromboembolism - blood; Thromboembolism - etiology; Thrombomodulin - blood; Human; E Selectin; Cell adhesion molecule; Cardiovascular disease; Malignant hemopathy; Hemopathy; Soluble form; Thrombosis; Blood plasma; Vascular disease; Myeloproliferative syndrome; Chronic; Complication; Thromboembolism; Thrombomodulin
• ISSN: 0361-8609; 1096-8652
• DOI: 10.1002/(SICI)1096-8652(199802)57:2<109::AID-AJH3>3.0.CO;2-#

Patients with chronic myeloproliferative disorders (CMD) show a high frequency of thrombosis. For this reason we evaluated endothelial cell markers, soluble adhesion molecule E‐selectin (sELAM), and thrombomodulin (TM) in 25 patients with CMD. Among them nine presented thromboses in their past history. Data were compared with those obtained in a group of healthy subjects and a group of patients with secondary thrombocytosis. The mean plasma concentrations of sELAM were elevated in patients with CMD, as compared with healthy subjects (81.27 ± 42.8 ng/ml vs. 41.75 ± 13; P < 0.02). Similarly, the mean plasma concentrations of sTM were increased in CMD patients in comparison with the control group (102.0 ± 73 ng/ml vs. 16.7 ± 9.6; P < 0.01). More markedly elevated sELAM levels were observed in CMD patients with thrombosis than in patients without thrombosis (113.16 ± 29.5 ng/ml vs. 55.11 ± 19.1 ng/ml; P < 0.001), while no significant difference was found between CMD patients without thrombosis and secondary thrombocytosis (50.72 ± 10.8 ng/ml). Plasma thrombomodulin values in CMD patients with thrombosis (131 ± 93.8 ng/ml) were higher than those without thrombosis (65.77 ± 43.9 ng/ml; P < 0.02). sTM values were also significantly increased in patients with secondary thrombocytosis (P < 0.01). It is speculated that the plasma, sELAM levels may reflect endothelium activation and that it is possibly useful in predicting the thrombotic risk in myeloproliferative disorders. Am. J. Hematol. 57:109–112, 1998. © 1998 Wiley‐Liss, Inc.